Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
663
datasets available to search
ShareScore release 0.9.0
Dataset results
663 results for “Statins”
Data from: Statin use and cognitive function: population-based observational study with long-term follow-up
Open the record for dataset details and reuse information.
Data from: Statin therapy in acute cardioembolic stroke with no guidance-based indication
<p><b>Objective</b> It is uncertain if patients with cardioembolic stroke and absence of a guidance-based indication for statin therapy should be administered a statin for prevention of subsequent vascular events. This study was performed to determine whether the statin therapy is beneficial to prevent major vascular events in this population.</p> <p><b>Methods</b> Using a prospective multicenter stroke registry database, we identified acute cardioembolic stroke patients who were hospitalized between 2008 and 2015. Patients who had other established indications for statin therapy according to current guideline were excluded. Major vascular event was defined as a composite of stroke recurrence, myocardial infarction and vascular death. We performed frailty model analysis with the robust sandwich variance estimator using the stabilized inverse probability of treatment weighting method to estimate hazard ratios of statin therapy on outcomes.</p> <p><b>Results </b>Of 6,124 cardioembolic stroke patients, 2,888 (male, 44.6%; mean age, 75.3 years with 95% confidence interval 74.8-75.8) were eligible; and 1,863 (64.5%) were on statin therapy during hospitalization. After a median follow-up of 359 days, cumulative incidences of major vascular events were 9.3% in the statin users and 20.5% in the non-users (p <0.001 by log-rank test). The adjusted hazard ratios of statin therapy was 0.39 (95% confidence interval, 0.31-0.48) for major vascular events; 0.81 (0.57-1.16) for stroke recurrence; 0.28 (0.21-0.36) for vascular death; and 0.53 (0.45-0.61) for all-cause death, respectively.</p> <p><b>Conclusion</b> Starting statin during acute stage of ischemic stroke may reduce the risk of major vascular events, vascular death and all-cause death in cardioembolic stroke patients with no guidance-based indication for statin.</p>
THE IMPACT OF STATIN THERAPY ON METABOLICALLY ASSOCIATED STEATOTIC LIVER DISEASE IN UZBEKISTAN: A SHORT-TERM STUDY
Open the record for dataset details and reuse information.
Data from: Non-industry sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis
Industry-sponsored clinical drug studies are associated with publication of outcomes that favor the sponsor, even when controlling for potential bias in the methods used. However, the influence of sponsorship bias has not been examined in preclinical animal studies. We performed a meta-analysis of preclinical statin studies to determine whether industry sponsorship is associated with either increased effect sizes of efficacy outcomes and / or risks of bias in a cohort of published preclinical statin studies. We searched Medline (January 1966 - April 2012) and identified 63 studies evaluating the effects of statins on atherosclerosis outcomes in animals. Two coders independently extracted study design criteria aimed at reducing bias, results for all relevant outcomes, sponsorship source, and investigator financial ties. The I2 statistic was used to examine heterogeneity. We calculated the standardized mean difference (SMD) for each outcome and pooled data across studies to estimate the pooled average SMD using random effects models. In a priori subgroup analyses, we assessed statin efficacy by outcome measured, sponsorship source, presence or absence of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. The effect of statins was significantly larger for studies sponsored by non-industry sources (-1.99; 95% CI -2.68, -1.31) versus studies sponsored by industry (-0.73; 95% CI -1.00, -0.47) (p value < 0.001). Statin efficacy did not differ by disclosure of financial conflict information, use of an optimal time window for outcome assessment, accounting for all animals, inclusion criteria, blinding, and randomization. Possible reasons for the differences between non-industry and industry sponsored studies, such as selective reporting of outcomes, require further study.
Data from: An investigation of the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomized controlled trials
Objectives: To investigate the therapeutic effects of statins with metformin on polycystic ovary syndrome (PCOS). Settings: Endocrinology department. Participants: MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials were searched until October 2014. Studies comparing statins and placebo, as well as the combination of statins and metformin and metformin alone, were included in the analysis. Interventions: Data were independently extracted by two researchers; any convergence was resolved by a third reviewer. Primary and secondary outcome measures: The following properties were extracted from the qualified trials to identify the effects of statins: clinical variables, metabolic characteristics, hormone outcomes, sign of inflammation, glucose parameters and insulin outcomes. Results: Data from four trials comparing statin and metformin with metformin alone were analysed. The combination of statins and metformin decreases the levels of C reactive protein (standardised mean difference (SMD) −0.91; 95% CI −1.81 to −0.02; p=0.046), triglyceride (SMD −1.37; 95% CI −2.46 to −0.28; p=0.014), total cholesterol (SMD −1.28; 95% CI −1.59 to −0.97; p=0.000) and low-density lipoprotein (LDL) cholesterol (SMD −0.74; 95% CI −1.03 to −0.44; p=0.000). However, the combined therapy fails to reduce fasting insulin (SMD −0.92; 95% CI −2.07 to 0.24; p=0.120), homeostasis model assessment of insulin resistance (SMD −1.15; 95% CI −3.36 to 1.06; p=0.309) and total testosterone (SMD −1.12; 95% CI −2.29 to 0.05; p=0.061). Analysis of the five trials comparing statin with placebo shows that statin monotherapy reduces LDL-cholesterol, triglyceride and total cholesterol. Conclusions: Combined statin and metformin therapy can improve lipid and inflammation parameters, but cannot effectively improve insulin sensitivity and reduce hyperandrogenism in women with PCOS. A large-scale randomised controlled study must be conducted to ascertain the long-term effects of the therapy.
High Potency Statins and the Risk of Diabetes
ClinicalTrials.gov study NCT02518503. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
ClinicalTrials.gov study NCT01259284. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Quality of Life in Patients With Statin-Associated Myopathy
ClinicalTrials.gov study NCT00850460. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)
ClinicalTrials.gov study NCT00395473. IPD Sharing: NO. Countries: 0. Publications: 1.
Statins Role in Acute Ischemic Stroke
ClinicalTrials.gov study NCT06371495. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Ezetimibe in Patients Hypo-responsive to Statins
ClinicalTrials.gov study NCT00965055. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
ClinicalTrials.gov study NCT04164888. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
ClinicalTrials.gov study NCT01976936. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Effect of a Fibrate and a Statin on Endothelial Dysfunction
ClinicalTrials.gov study NCT00491400. IPD Sharing: Not stated. Countries: 1. Publications: 0.
StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
ClinicalTrials.gov study NCT03882177. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vitamin D Replacement: The Effect on Statin-Related Myalgias
ClinicalTrials.gov study NCT01022398. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
ClinicalTrials.gov study NCT00375349. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Investigation of the Gut Microbiome and Statin Response
ClinicalTrials.gov study NCT04098003. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)
ClinicalTrials.gov study NCT06559072. IPD Sharing: YES. Countries: 1. Publications: 0.
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
ClinicalTrials.gov study NCT00673660. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.